Alliance Pharma PLC Marketing Authorisation for Xonvea in Ireland (6874V)
April 10 2019 - 1:01AM
UK Regulatory
TIDMAPH
RNS Number : 6874V
Alliance Pharma PLC
10 April 2019
10 April 2019
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Marketing Authorisation for Xonvea in Ireland
Alliance Pharma plc (AIM: APH), the international healthcare
group, announces that Xonvea(R) has gained marketing approval in
the Republic of Ireland from the country's medicines regulator, the
Health Products Regulatory Authority, for the treatment of nausea
and vomiting of pregnancy where conservative management has
failed.
Approval in Ireland paves the way for Alliance's first launch of
Xonvea outside the UK, where the product was in-licensed from
Duchesnay Inc. of Canada in 2015 and launched in October 2018. In
Ireland it has been approved for the same indication, nausea and
vomiting of pregnancy where conservative management has failed.
In Ireland, as in the UK, nausea and vomiting of pregnancy
("NVP") is the most common medical condition in pregnancy,
affecting approximately 46,500 women in Ireland each year* (70%-80%
of pregnant women). Research shows that up to 40% of pregnant women
report symptoms of nausea and vomiting sufficiently severe to
interfere with daily life with at least 1 in 100-150 women
hospitalised with the condition in Ireland each year.
It is expected that Xonvea will be launched in Ireland in Q4
2019 and will be marketed directly by Alliance's in-country sales
and marketing team.
*Hyperemesis Ireland website
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
Corporate Broking: James Black
Investec Bank plc + 44 (0)20 7597 5970
Corporate Finance: Daniel Adams /
Ed Thomas
Corporate Broking: Patrick Robb /
Tejas Padalkar
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with affiliate offices in Europe,
the Far East and the US and wide international reach through an
extensive network of distributors, generating sales in more than
100 countries.
We currently own or license the rights to more than 90
pharmaceutical and consumer healthcare products, which are managed
on a portfolio basis according to their growth potential.
Promotional investment is focussed on a small number of brands with
significant international or multi-territory reach. The remainder
of the portfolio comprises products which are sold in a limited
number of local markets and require little or no promotional
investment.
Our tried and tested 'Buy and Build' strategy, allows us to
benefit both from organic growth opportunities and from enhancing
our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
About Duchesnay Inc.
Duchesnay Inc. is a specialty pharmaceutical company with a
long-standing commitment to women's health. Until recently, the
company focused on filling the void in terms of scientific research
and education and on developing pharmacological solutions for use
during pregnancy and breastfeeding. Today, Duchesnay has broadened
its portfolio of products to offer therapeutic options that help to
meet the health and quality of life needs of women and their family
members at different stages of their lives. For more information
about Duchesnay, please visit duchesnay.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
REALLFEASTIAIIA
(END) Dow Jones Newswires
April 10, 2019 02:01 ET (06:01 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2024 to May 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From May 2023 to May 2024